Growing Emphasis On Personalized Medicine Fueling The Growth Of The Market Due To Advancements In Genomic Technologies Driving Market Acceleration in the T Cell Specific Surface Glycoprotein CD28 Industry, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the T Cell Specific Surface Glycoprotein CD28 Market Size By 2025?
In recent times, the market for the T cell-specific surface glycoprotein known as CD28 has expanded at a brisk pace. Forecasts suggest an increase from $1.47 billion in 2024 to approximately $1.62 billion in 2025, embodying a compound annual growth rate (CAGR) of 10.1%. This historical growth is largely due to factors such as the increased focus on immunotherapy research, a surge in cancer prevalence, more reported instances of autoimmune diseases, augmented number of clinical trials, and a growing preference for monoclonal antibodies.

How Big Is the T Cell Specific Surface Glycoprotein CD28 Market Size Expected to Grow by 2029?
In the coming years, the market for the T cell-specific surface glycoprotein CD28 is predicted to observe robust growth, reaching $2.35 billion by 2029 with a compound annual growth rate (CAGR) of 9.8%. This boost in market growth during the forecasted period can be credited to the escalating demand for personalized medicine and the increasing emphasis on T-cell-based therapies. Other contributing elements include the growing consciousness of immuno-oncology, a burgeoning pipeline of targeted treatments, considerable investment by pharmaceutical companies, and the burgeoning applications for chronic diseases. Notable market trends during this period include advancements in cell engineering techniques, the progressive development of bispecific antibodies, innovation in specific immunotherapies, the incorporation of AI in medication discovery, and progress in biologics manufacturing.

View the full report here:
https://www.thebusinessresearchcompany.com/report/t-cell-specific-surface-glycoprotein-cd28-global-market-report

Which Key Market Drivers Powering T Cell Specific Surface Glycoprotein CD28 Market Expansion and Growth?
The surge in focus on personalized medicine is anticipated to boost the T cell-specific surface glycoprotein CD28 market's expansion. Personalized medicine is a healthcare strategy that customizes treatments according to each patient's genetics, environment, and lifestyle for optimized results and enhanced care. The call for personalized medicine is rising due to technological advancements in genomics, permitting the accurate detection of genetic discrepancies and personalized treatments for individuals. The T cell-specific surface glycoprotein CD28 bolsters personalized medicine by facilitating targeted immune modulation, hence increasing the precision and efficacy of therapies. It augments treatment results by triggering optimal T cell activation and enhancing patient-specific immune responses. For example, in February 2024, as per the Personalized Medicine Coalition (PMC), a non-profit organization based in the US, the U.S. Food and Drug Administration (FDA) gave approval to 26 new personalized medicines in 2023, a rise from 12 approved in 2022. Thus, the heightened focus on personalized medicine is propelling the growth of the T cell-specific surface glycoprotein CD28 market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp

What Are the Key Trends Driving T Cell Specific Surface Glycoprotein CD28 Market Growth?
Leading firms working in the T cell-specific surface glycoprotein CD28 market are concentrating on the development of ground-breaking products like combination immunotherapies to increase T cell stimulation, anti-tumor efficiency, and improve the results of patient treatment. Combination immunotherapies are therapeutic methods that utilize multiple immune-oriented strategies to strengthen the body's disease resistance. For example, in February 2025, a US biopharmaceutical organization, Rondo Therapeutics Inc., unveiled preclinical results for RNDO 564, an innovative CD28 Nectin 4 costimulatory bispecific antibody for pervasive bladder cancer. The product is designed to selectively trigger CD28 on T cells when binding to Nectin-4-expressing cancer cells, amplifying T-cell-mediated tumor destruction while reducing unwanted toxicity. The released data show powerful anti-tumor effects in preclinical scenarios, advocating further progression as a possible cure for patients living with metastatic urothelial carcinoma.

What Are the Emerging Segments in the T Cell Specific Surface Glycoprotein CD28 Market?
The t cell specific surface glycoprotein cd28 market covered in this report is segmented

1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types
2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry
3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers
4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research
5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories

Subsegments:
1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships
2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations
3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering
4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27429&type=smp

Who Are the Global Leaders in the T Cell Specific Surface Glycoprotein CD28 Market?
Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton dic*kinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.

Which are the Top Profitable Regional Markets for the T Cell Specific Surface Glycoprotein CD28 Industry?
North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27429

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.